ArticleInfection2022
Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit.
Article in Infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it, 147 citations in OpenAlex.
- Risk factors for bloodstream infection in COVID-19 patients in intensive care units: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- AI-assisted MALDI-TOF MS for identifying carbapenem resistance in clinicalEmerging microbes & infections · 2026Article
- Healthcare-Associated Infections in Critically Ill COVID-19 Patients Across Evolving Pandemic Waves: A Retrospective ICU Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Potential of Eugenia brejoensis (Mazine) Essential Oil in Combating Multidrug-Resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa.Chemistry & biodiversity · 2026Article
- Carbapenem-resistantFrontiers in medicine · 2026Article
- Synthesis of Acinetobacter baumannii Lipid A(s) and derivatives and their structure-immunostimulatory activity relationships.Communications chemistry · 2025Article
- Diversity versus clonality in carbapenem-resistant A. baumannii: a two-year surveillance study in four intensive care units at a large teaching hospital in Rome, Italy.Antimicrobial resistance and infection control · 2025Article
- Risk factors for the development of hospital-acquired pneumonia in patients with carbapenem-resistant Acinetobacter baumannii respiratory colonization and the role of multisite colonization: a multicenter retrospective study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Diabetes Mellitus and Multidrug-Resistant Gram-Negative Bacterial Infections in Critically Ill COVID-19 Patients: A Retrospective Observational Study.Diagnostics (Basel, Switzerland) · 2025Article
- Research and predictive analysis of the disease burden of bloodstream infectious diseases in China.BMC infectious diseases · 2025Article
- Phenotypical and Molecular Characterization ofLife (Basel, Switzerland) · 2025Article
- Colistin Treatment Outcomes in Gram-Negative Bacterial Infections in the Northeast of Romania: A Decade of Change Through Pandemic Challenges.Antibiotics (Basel, Switzerland) · 2025Article
- Dual threat: Susceptibility mechanisms and treatment strategies for COVID-19 and bacterial co-infections.Computational and structural biotechnology journal · 2025Review
- AaeAP2a, a scorpion-derived antimicrobial peptide, combats carbapenem-resistantFrontiers in microbiology · 2025Article
- Humoral response induced after intranasal vaccination with heat inactivatedFrontiers in immunology · 2025Article
- Bacteriological Spectrum and Drug Resistance Among Patients Associated With Bloodstream Infection in Intensive Care Units in the Affiliated Hospital of Jiaxing University From 2021 to 2023.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- Inserting Omp22 into the flagellin protein, replacing its hypervariable region, results in stronger protection against lethal Acinetobacter baumannii infection.Scientific reports · 2024Article
- Risk factors for infection after carbapenem-resistant Acinetobacter baumannii colonization.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Observational
- Outbreak with OXA-23-producing Acinetobacter baumannii in a COVID-19 ICU cohort: unraveling routes of transmission.Antimicrobial resistance and infection control · 2024Article
- Exploring the metabolic profile of A. baumannii for antimicrobial development using genome-scale modeling.PLoS pathogens · 2024Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSuperinfections in patients hospitalized in intensive care unit (ICU) are an important and challenging complication, also in COVID-19. However, no definitive data are available about the role of multidrug-resistant Acinetobacter baumannii (MDR-AB) in COVID-19.
methodsThis was a single-center, cross-sectional study including patients with MDR-AB infections admitted to ICU with or without COVID-19, between January 2019 and January 2021. The primary objective of the study was to evaluate risk factor for MDR-AB infections in ICU patients hospitalized for COVID-19 or other etiology. The secondary endpoints were 30-days mortality in all study population and risk factors associated with development of bloodstream infection (BSI).
resultsDuring the study period 32 adults with COVID-19 were enrolled and compared with 115 patients admitted in the same ICU for other reasons. We observed a total of 114 deaths, with a survival rate of 29.3%: 18.8% in COVID-19 and 32.2% in control group. Relative risk for MDR-AB infection in COVID-19 showed that serum lactate levels mmol/l > 2, Acinetobacter baumannii colonization, BSI and steroid therapy were observed more frequently in COVID-19 patients. Cox regression analysis showed that serum lactate levels > 2 mmol/l, Acinetobacter baumannii colonization, BSI, and steroid therapy were associated with 30-days mortality. Finally, patients with COVID-19, white blood cells count > 11,000 mm
conclusionsOur data highlight the impact of BSI on outcome, the role of Acinetobacter baumannii colonization and the use of steroids on the risk to develop MDR-AB infections also during COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.